-- Federal Court Enters Consent Judgment Terminating Litigation --
MADISON, N.J., July 16 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) and
Impax Laboratories Inc. today announced that all conditions of a settlement
of the U.S. patent infringement litigation pertaining to Impax's proposed
generic capsule formulation of Wyeth's EFFEXOR XR(R) antidepressant have
been approved by the United States District Court for the District of
Delaware. The Court entered a consent judgment resulting in termination of
the litigation effective today.
Under the terms of the settlement, Wyeth has granted Impax a license
that would permit Impax to launch its capsule formulation of Effexor XR on
or after June 1, 2011, subject to earlier launch in limited circumstances,
but in no event earlier than January 1, 2011. Impax will pay Wyeth a
royalty on sales of this generic product.
The parties also have agreed that Impax will utilize its
neurology-focused sales force to promote a product to be named by Wyeth.
Other terms of this agreement are confidential and were not disclosed.
Wyeth is one of the world's largest research-driven pharmaceutical and
health care products companies. It is a leader in the discovery,
development, manufacturing and marketing of pharmaceuticals, vaccines,
biotechnology products, nutritionals and non-prescription medicines that
improve the quality of life for people worldwide. The Company's major
divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort
Dodge Animal Health.
The statements in this press release that are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied by such statements. These risks and uncertainties include, without
limitation, the inherent uncertainty of the timing and success of, and
expense associated with, research, development, regulatory approval and
commercialization of our products and pipeline products; government cost-
containment initiatives; restrictions on third-party payments for our
products; substantial competition in our industry, including from branded
and generic products; emerging data on our products and pipeline products;
the importance of strong performance from our principal products and our
anticipated new product introductions; the highly regulated nature of our
business; product liability, intellectual property and other litigation
risks and environmental liabilities; uncertainty regarding our intellectual
property rights and those of others; difficulties associated with, and
regulatory compliance with respect to, manufacturing of our products; risks
associated with our strategic relationships; economic conditions including
interest and currency exchange rate fluctuations; changes in generally
accepted accounting principles; trade buying patterns; the impact of
legislation and regulatory compliance; risks and uncertainties associated
with global operations and sales; and other risks and uncertainties,
including those detailed from time to time in our periodic reports filed
with the Securities and Exchange Commission, including our current reports
on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K,
particularly the discussion under the caption "Item 1A, Risk Factors" in
our Annual Report on Form 10-K for the year ended December 31, 2007, which
was filed with the Securities and Exchange Commission on February 29, 2008.
The forward-looking statements in this press release are qualified by these
risk factors. We assume no obligation to publicly update any
forward-looking statements, whether as a result of new information, future
developments or otherwise.
SOURCE Wyeth
 back to top
Related links:
http://www.wyeth.com
CONTACT:
Media Contact: Douglas Petkus,
+1-973-660-5218; Investor Contact: Justin Victoria,
+1-973-660-5340, both of Wyeth
|
